Sarah Will

Robust anti‐obesity and metabolic effects of a dual <scp>GLP</scp> ‐1/glucagon receptor peptide agonist in rodents and non‐human primates

Susan Henderson, Anish Konkar, David C. Hornigold et al. · Diabetes Obesity and Metabolism · 2016 · 235 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

Dean R. Artis, Jack J. Lin, Chao Zhang et al. · Proceedings of the National Academy of Sciences · 2008 · 148 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists

David V. Erbe, Katherine Gartrell, Yanling Zhang et al. · Vascular Pharmacology · 2006 · 137 citations

Medicine, Cardiology, Pharmacology +13

Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease

Sergei Pechenov, Jefferson D. Revell, Sarah Will et al. · Scientific Reports · 2021 · 74 citations · Full text

Pharmacy, Endocrinology, Pharmacology +17

Disruption of G Protein-Coupled Receptor 39 Impairs Insulin Secretion in Vivo

Frédéric Tremblay, Ann-Marie Richard, Sarah Will et al. · Endocrinology · 2009 · 67 citations · Full text

Life Sciences, Endocrinology, Aging +8